Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aclidinium/formoterol twice daily versus tiotropium once daily for 24-hour lung hyperinflation in COPD
NL-OMON49226Phase 4Recruiting
- Sponsor
- CIRO
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of aclidinium and tiotropium in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by CIRO. Primary endpoint: 24-hour static hyperinflation. Started Jun 2017; status: recruiting.
02
Drugs
aclidiniumtiotropium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON49226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49226.